Abstract
The most common renal cancer is renal cell carcinoma (RCC), which arises from the renal parenchyma. The global incidence of RCC has increased over the past two decades by 2% per year. RCC is the most lethal of the common urological cancers: despite diagnostic advances, 20–30% of patients present with metastatic disease. A clearer understanding of the genetic basis of RCC has led to immune-based and targeted treatments for this chemoresistant cancer. Despite promising results in advanced disease, overall response rates and durable complete responses are rare. Surgery remains the main treatment modality, especially for organ-confined disease, with a selective role in advanced and metastatic disease. Smaller tumours are increasingly managed with biopsy, minimally invasive interventions and surveillance. The future promises multimodal, integrated and personalized care, with further understanding of the disease leading to new treatment options.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: kidney and renal pelvis cancer [online], (2013).
Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).
Ferlay, J., Parkin, D. M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765–781 (2010).
Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W. & Charbonneau, C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34, 193–205 (2008).
Chow, W. H. & Devesa, S. S. Contemporary epidemiology of renal cell cancer. Cancer J. 14, 288–301 (2008).
Chow, W. H., Dong, L. M. & Devesa, S. S. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7, 245–257 (2010).
Lipworth, L., Tarone, R. E. & McLaughlin, J. K. The epidemiology of renal cell carcinoma. J. Urol. 176, 2353–2358 (2006).
Hunt, J. D., van der Hel, O. L., McMillan, G. P., Boffetta, P. & Brennan, P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int. J. Cancer 114, 101–108 (2005).
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F. & Zwahlen, M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–578 (2008).
Pischon, T. et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int. J. Cancer 118, 728–738 (2006).
Weikert, S. et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am. J. Epidemiol. 167, 438–446 (2008).
Choi, Y. et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int. J. Cancer 132, 625–634 (2013).
Delahunt, B. & Thornton, A. Renal cell carcinoma. A historical perspective. J. Urol. Pathol. 4, 31–49 (1996).
Carson, W. J. Solitary cysts of the kidney. Ann. Surg. 87, 250–256 (1928).
Newcomb, W. D. The pathology of tumours of the urinary tract: (section of radiology). Proc. R. Soc. Med. 32, 1455–1467 (1939).
Foot, N. C., Humphreys, G. A. & Whitmore, W. F. Renal tumors: pathology and prognosis in 295 cases. J. Urol. 66, 190–200 (1951).
Oberling, C., Riviere, M. & Haguenau, F. Ultrastructure of the clear cells in renal carcinomas and its importance for the demonstration of their renal origin. Nature 186, 402–403 (1960).
Thoenes, W., Storkel, S. & Rumpelt, H. J. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol. Res. Pract. 181, 125–143 (1986).
Delahunt, B. & Eble, J. N. History of the development of the classification of renal cell neoplasia. Clin. Lab. Med. 25, 231–246 (2005).
Storkel, S. et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80, 987–989 (1997).
Kovacs, G. et al. The Heidelberg classification of renal cell tumours. J. Pathol. 183, 131–133 (1997).
Eble, J. N., Sauter, G., Epstein, J. I. & Sesterhenn, I. A. (Eds). World Health Organization Classification of Tumours. Pathology and genetics of tumours of the urinary system and male genital organs (IARC Press, 2004).
Srigley, J. R. et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am. J. Surg. Pathol. 37, 1469–1489 (2013).
Sidhar, S. K. et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum. Mol. Genet. 5, 1333–1338 (1996).
Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477–2490 (2005).
Linehan, W. M., Walther, M. M. & Zbar, B. The genetic basis of cancer of the kidney. J. Urol. 170, 2163–2172 (2003).
Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277–285 (2010).
Cancer.Net. Von Hippel–Lindau Syndrome [online], (2013).
Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317–1320 (1993).
Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85–90 (1994).
Brauch, H. et al. Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p. World J. Urol. 12, 162–168 (1994).
Zbar, B., Brauch, H., Talmadge, C. & Linehan, M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327, 721–724 (1987).
Zbar, B. et al. Hereditary papillary renal cell carcinoma. J. Urol. 151, 561–566 (1994).
Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68–73 (1997).
Sudarshan, S. & Linehan, W. M. Genetic basis of cancer of the kidney. Semin. Oncol. 33, 544–551 (2006).
Launonen, V. et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl Acad. Sci. USA 98, 3387–3392 (2001).
Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406–410 (2002).
Birt, A. R., Hogg, G. R. & Dubé, W. J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch. Dermatol. 113, 1674–1677 (1977).
Toro, J. R. et al. Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch. Dermatol. 135, 1195–1202 (1999).
Schmidt, L. S. et al. Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am. J. Hum. Genet. 69, 876–882 (2001).
Khoo, S. K. et al. Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene 20, 5239–5242 (2001).
Birnbaum, B. A., Hindman, N., Lee, J. & Babb, J. S. Multi-detector row CT attenuation measurements: assessment of intra- and interscanner variability with an anthropomorphic body CT phantom. Radiology 242, 109–119 (2007).
Pretorius, E. S., Wickstrom, M. L. & Siegelman, E. S. MR imaging of renal neoplasms. Magn. Reson. Imaging Clin. N. Am. 8, 813–836 (2000).
Volpe, A. et al. The natural history of incidentally detected small renal masses. Cancer 100, 738–745 (2004).
Rendon, R. A. et al. The natural history of small renal masses. J. Urol. 164, 1143–1147 (2000).
Gill, I. S., Aron, M., Gervais, D. A. & Jewett, M. A. Clinical practice. Small renal mass. N. Engl. J. Med. 362, 624–634 (2010).
Nguyen, M. M., Gill, I. S. & Ellison, L. M. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J. Urol. 176, 2397–2400 (2006).
Appelbaum, A. H., Kamba, T. T., Cohen, A. S., Qaisi, W. G. & Amirkhan, R. H. Effectiveness and safety of image-directed biopsies: coaxial technique versus conventional fine-needle aspiration. South. Med. J. 95, 212–217 (2002).
Volpe, A. et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J. Urol. 178, 379–386 (2007).
Leveridge, M. J. et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur. Urol. 60, 578–584 (2011).
Volpe, A. et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J. Urol. 180, 2333–2337 (2008).
Poletajew, S., Antoniewicz, A. A. & Borowka, A. Kidney removal: the past, presence, and perspectives: a historical review. Urol. J. 7, 215–223 (2010).
Robson, C. J. Radical nephrectomy for renal cell carcinoma. J. Urol. 89, 37–42 (1963).
Clayman, R. V. et al. Laparoscopic nephrectomy. N. Engl. J. Med. 324, 1370–1371 (1991).
Clayman, R. V. et al. Laparoscopic nephrectomy: initial case report. J. Urol. 146, 278–282 (1991).
Licht, M. R., Novick, A. C. & Goormastic, M. Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J. Urol. 152, 39–42 (1994).
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).
Campbell, S. C. et al. Guideline for management of the clinical T1 renal mass. J. Urol. 182, 1271–1279 (2009).
Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58, 398–406 (2010).
Herr, H. W. A history of partial nephrectomy for renal tumors. J. Urol. 173, 705–708 (2005).
Vermooten, V. Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma. J. Urol. 64, 200–208 (1950).
Uzzo, R. G. & Novick, A. C. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J. Urol. 166, 6–18 (2001).
Huang, W. C., Elkin, E. B., Levey, A. S., Jang, T. L. & Russo, P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? J. Urol. 181, 55–61 (2009).
Miller, D. C. et al. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 112, 511–520 (2008).
Abouassaly, R., Alibhai, S. M., Tomlinson, G. A., Urbach, D. R. & Finelli, A. The effect of age on the morbidity of kidney surgery. J. Urol. 186, 811–816 (2011).
Van Poppel, H. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59, 543–552 (2011).
Yossepowitch, O. et al. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J. Urol. 179, 2158–2163 (2008).
Bensalah, K. et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur. Urol. 57, 466–471 (2010).
Raz, O. et al. Positive surgical margins with renal cell carcinoma have a limited influence on long-term oncological outcomes of nephron sparing surgery. Urology 75, 277–280 (2010).
Gill, I. S. et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J. Urol. 178, 41–46 (2007).
Shapiro, E., Benway, B. M., Wang, A. J. & Bhayani, S. B. The role of nephron-sparing robotic surgery in the management of renal malignancy. Curr. Opin. Urol. 19, 76–80 (2009).
Rogers, C. G., Singh, A., Blatt, A. M., Linehan, W. M. & Pinto, P. A. Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur. Urol. 53, 514–521 (2008).
Permpongkosol, S. et al. Long-term survival analysis after laparoscopic radical nephrectomy. J. Urol. 174, 1222–1225 (2005).
Portis, A. J. et al. Long-term followup after laparoscopic radical nephrectomy. J. Urol. 167, 1257–1262 (2002).
Burgess, N. A. et al. Randomized trial of laparoscopic v open nephrectomy. J. Endourol. 21, 610–613 (2007).
Blom, J. H. et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur. Urol. 55, 28–34 (2009).
Pantuck, A. J. et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J. Urol. 169, 2076–2083 (2003).
O'Malley, R. L., Godoy, G., Kanofsky, J. A. & Taneja, S. S. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J. Urol. 181, 2009–2017 (2009).
Kutikov, A. et al. Routine adrenalectomy is unnecessary during surgery for large and/or upper pole renal tumors when the adrenal gland is radiographically normal. J. Urol. 185, 1198–1203 (2011).
Aron, M. & Gill, I. S. Minimally invasive nephron-sparing surgery (MINSS) for renal tumours. Part II: probe ablative therapy. Eur. Urol. 51, 348–357 (2007).
Uchida, M., Imaide, Y., Sugimoto, K., Uehara, H. & Watanabe, H. Percutaneous cryosurgery for renal tumours. Br. J. Urol. 75, 132–136 (1995).
Hoffmann, N. E. & Bischof, J. C. The cryobiology of cryosurgical injury. Urology 60, 40–49 (2002).
Zlotta, A. R. et al. Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J. Endourol. 11, 251–258 (1997).
Raj, G. V., Reddan, D. J., Hoey, M. F. & Polascik, T. J. Management of small renal tumors with radiofrequency ablation. Urology 61, 23–29 (2003).
Kunkle, D. A. & Uzzo, R. G. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 113, 2671–2680 (2008).
Heuer, R. et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur. Urol. 57, 223–232 (2010).
Zagoria, R. J. et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am. J. Roentgenol. 189, 429–436 (2007).
Johnson, D. B. et al. Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review. J. Urol. 172, 874–877 (2004).
Bosniak, M. A. Observation of small incidentally detected renal masses. Semin. Urol. Oncol. 13, 267–272 (1995).
Jewett, M. A. et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur. Urol. 60, 39–44 (2011).
Jewett, M. et al. Management of kidney cancer: canadian kidney cancer forum consensus update 2011. Can. Urol. Assoc. J. 6, 16–22 (2012).
Frank, I. et al. Solid renal tumors: an analysis of pathological features related to tumor size. J. Urol. 170, 2217–2220 (2003).
Chawla, S. N. et al. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J. Urol. 175, 425–431 (2006).
Jewett, M. A. & Zuniga, A. Renal tumor natural history: the rationale and role for active surveillance. Urol. Clin. North Am. 35, 627–634 (2008).
Crispen, P. L. et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115, 2844–2852 (2009).
Kouba, E., Smith, A., McRackan, D., Wallen, E. M. & Pruthi, R. S. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J. Urol. 177, 466–470 (2007).
Kates, M., Korets, R., Sadeghi, N., Pierorazio, P. M. & McKiernan, J. M. Predictors of locally advanced and metastatic disease in patients with small renal masses. BJU Int. 109, 1463–1467 (2012).
Patel, N. et al. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int. 110, 1270–1275 (2012).
Smaldone, M. C., Corcoran, A. T. & Uzzo, R. G. Active surveillance of small renal masses. Nat. Rev. Urol. 10, 266–274 (2013).
Haferkamp, A. et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J. Urol. 177, 1703–1708 (2007).
Oto, A., Herts, B. R., Remer, E. M. & Novick, A. C. Inferior vena cava tumor thrombus in renal cell carcinoma: staging by MR imaging and impact on surgical treatment. AJR Am. J. Roentgenol. 171, 1619–1624 (1998).
Lawindy, S. M. et al. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int. 110, 926–939 (2012).
Wagner, B. et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur. Urol. 55, 452–459 (2009).
Margulis, V. et al. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer 109, 2025–2030 (2007).
Capitanio, U. et al. Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). BJU Int. 104, 795–799 (2009).
Sciarra, A. et al. The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? Crit. Rev. Oncol. Hematol. 81, 151–162 (2012).
Gupta, S. & Spiess, P. E. The prospects of pazopanib in advanced renal cell carcinoma. Ther. Adv. Urol. 5, 223–232 (2013).
Clark, J. I. et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol. 21, 3133–3140 (2003).
Messing, E. M. et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol. 21, 1214–1222 (2003).
Siva, S., Pham, D., Gill, S., Corcoran, N. M. & Foroudi, F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 110, E737–E743 (2012).
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).
Rini, B. I. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422–5428 (2008).
Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061–1068 (2010).
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722–731 (2013).
Yang, J. C. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127–3132 (2003).
Hanzly, M. et al. High-dose Interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology 83, 1129–1134 (2014).
Flanigan, R. C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655–1659 (2001).
Flanigan, R. C. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071–1076 (2004).
Mickisch, G. H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001).
Chowdhury, S., Harper, P. G. & Choueiri, T. K. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. Nat. Clin. Pract. Oncol. 5, 698–699 (2008).
Choueiri, T. K. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185, 60–66 (2011).
Cowey, C. L. et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28, 1502–1507 (2010).
Abel, E. J. et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol. 59, 10–15 (2011).
van der Veldt, A. A. et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14, 2431–2436 (2008).
Krabbe, L. M., Haddad, A. Q., Westerman, M. E. & Margulis, V. Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J. Urol. 32, 615–622 (2014).
Galazi, M., Rodriguez-Vida, A., Josephides, E., Chau, N. M. & Chowdhury, S. Cytoreductive nephrectomy: past, present and future. Expert Rev. Anticancer Ther. 14, 271–277 (2014).
Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet 373, 1119–1132 (2009).
Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530–2540 (1999).
Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009).
Heng, D. Y. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14, 141–148 (2013).
McKay, R. R. et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur. Urol. 65, 577–584 (2014).
Sonpavde, G., Sudarshan, S. & Escudier, B. Do the sites of metastases provide additional information regarding prognosis and biology in renal cell carcinoma? Eur. Urol. 65, 585–586 (2014).
Kavolius, J. P. et al. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 16, 2261–2266 (1998).
Alt, A. L. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117, 2873–2882 (2011).
Syrios, J., Kechagias, G. & Tsavaris, N. Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature. J. Med. Case Rep. 6, 303 (2012).
Voss, M. H., Hsieh, J. J. & Motzer, R. J. Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma. Cancer J. 19, 299–306 (2013).
Richey, S. L. & Hutson, T. E. Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma. Cancer J. 19, 307–310 (2013).
Cho, D. Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma. Cancer J. 19, 311–315 (2013).
Bailey, A. & McDermott, D. F. Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics. Cancer J. 19, 348–352 (2013).
Pal, S. K., Hu, A. & Figlin, R. A. A new age for vaccine therapy in renal cell carcinoma. Cancer J. 19, 365–370 (2013).
Walter, S. et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254–1261 (2012).
Harshman, L. C. & Choueiri, T. K. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 19, 316–323 (2013).
Brugarolas, J. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J. 19, 324–332 (2013).
Raju, T. N. The Nobel chronicles. 1979: Allan MacLeod Cormack (b 1924); and Sir Godfrey Newbold Hounsfield (b 1919). Lancet 354, 1653 (1999).
Bukowski, R. M. et al. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. J. Natl Cancer Inst. 82, 143–146 (1990).
Quesada, J. R., Swanson, D. A., Trindade, A. & Gutterman, J. U. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res. 43, 940–947 (1983).
Gill, I. S., Sung, G. T., Hsu, T. H. & Meraney, A. M. Robotic remote laparoscopic nephrectomy and adrenalectomy: the initial experience. J. Urol. 164, 2082–2085 (2000).
Algaba, F. et al. in Kidney cancer (eds Kirkali, Z. & Mulders, P.) 47–72 (ICUD-EAU, 2011).
Author information
Authors and Affiliations
Contributions
J.R.B. researched the data for the article. Both authors provided substantial contributions to discussions of the content. J.R.B. wrote the article. Both authors contributed to review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Bhatt, J., Finelli, A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol 11, 517–525 (2014). https://doi.org/10.1038/nrurol.2014.194
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.194
This article is cited by
-
Establishment and validation of a novel peroxisome-related gene prognostic risk model in kidney clear cell carcinoma
BMC Urology (2024)
-
Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance
Cancer and Metastasis Reviews (2024)
-
Role of the human solute carrier family 14 member 1 gene in hypoxia-induced renal cell carcinoma occurrence and its enlightenment to cancer nursing
BMC Molecular and Cell Biology (2023)
-
Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review
Medical Oncology (2023)
-
Novel imino-thiazoloquinoxaline derivatives against renal cell carcinoma: less radiation-damaging approach
Medicinal Chemistry Research (2023)